What is Lou Gehrig’s disease?

The Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s disease, kills motor neurons to weaken muscles. Muscular dystrophy progresses gradually in the four limbs and sometimes, it paralyzes respiratory muscle in the end to lead to death.

How is Lou Gehrig’s disease treated?

The medicine called Rilutek was introduced in the 1990s and has been utilized since then. Rilutek is used with the hope to extend 3 months of life if administered for 2 years. However, many evaluate the medicine brings only less than satisfactory effect on living quality improvement such as muscular recovery. In this situation, a recently-developed cell medicine (Neuronata R Injection) attracts increasing interest as it helps alleviate the disease if utilized in parallel.

What is the medicine, Neuronata R Injection?

Neuronata R Injection was developed as the world’s first stem cell medicine for Lou Gehrig’s disease. Its efficacy to slow or stop the disease progress has been proven. The principle of its mechanism is to utilize nerve protection and anti-inflammation-mediated immuneregulation to help reduce motor neuron destruction and neural inflammatory reaction.

About Myongji Lou Gehrig Center

Provides diagnosis, comprehensive treatment and personal-tailored therapeutic service to patients based on the cooperation of specialized medical staff.
Provides multidisciplinary treatment encompassing neurology, rehabilitation medicine, internal medicine and otolaryngology.
Provides care service based on the cooperation of the rehabilitation team, speech therapy team and nutrition team
Provides practical therapeutic program consisting of cell therapy + rehabilitation therapy + dietary prescription.

세계 최초 루게릭병 줄기세포치료제 ‘뉴로나타-알주(Neuronata-R inj.)’ 투여

환자 본인의 줄기세포를 분리, 배양해 투여

사멸되는 운동신경세포의 생존을 연장

KFDA 공식 품목허가 승인 제제

입원 기간 환자 상태별 1:1 맞춤형 재활치료

근육 경직 방지 및 일상생활능력 유지

일반재활, 호흡재활, 연하재활, 일상생활동작재활 등

전문 영양사의 환자 맞춤형 영양 평가 및 메뉴 구성, 조리법 관리

체중 유지를 위한 영양 농축 식품, 보충제, 음료 등 제공

양질의 단백질, 수분, 섬유소, 항산화 비타민 등 맞춤형 식단

   Treatment schedule (subject to change according to a patient’s own status)
1st hospitalization (7 days) bone marrow harvest, general chemical test, immunology test, diagonal blood test, swallowing function test, respiratory function test, education on rehabilitation therapy
Re-hospitalization in 30 days after the 1st hospitalization
2nd hospitalization (31 days) 1st injection, basic blood test, swallowing function test, respiratory function test, rehabilitation therapy, dietary prescription, side effect monitoring